The increase in antidepressant therapy based supplements along with omega-3 fatty acid levels does not improve depression in patients with coronary disease, according to a study by the University of Washington published today in JAMA.
Contrary to what is apparent from published studies, a new work developed by a team at Washington University in St. Louis, indicates that the therapy increased from antidepressants (sertraline) with supplements of omega-3 fatty acids levels does not improve depression in patients with coronary heart disease.
The study, led by Robert M. Carney, of that university, and published today in The Journal of the American Medical Association, included 122 patients who received 50 milligrams daily of sertraline and who were randomized to receive 2 grams daily of omega-3 acid in the as ethyl esters or placebo capsules for ten weeks. The authors have shown no differences in the improvement according to the Beck Depression Questionnaire I and II among the different groups.
During the ten weeks they were under observation, and placebo groups did not differ omega-3 in terms of anxiety or depression. There were no significant differences in remission rates or response to therapy between the two groups.
